bioLytical Laboratories Inc. Receives its CE Mark for the iStatis COVID-19 Antigen Home Test
bioLytical Laboratories Inc. announced today that it is launching a new platform, iStatis, and has received its CE Mark for immediate market entry into Europe for its iStatis COVID-19 Antigen Home Test
- From the makers of INSTI®, bioLytical launches a new platform, iStatis, created to ensure every person in the world has access to reliable testing
- bioLytical has received its CE Mark for the iStatis COVID-19 Antigen Home Test for immediate entry to the European market
- The test is portable and can be performed at home with easy-to-understand results and no additional readers or machinery needed
- Test performance in clinical studies demonstrated an industry-leading 100% accuracy
- bioLytical’s quality system is ISO 13485:2016 MDSAP certified
RICHMOND, British Columbia, March 21, 2022 (GLOBE NEWSWIRE) -- bioLytical Laboratories Inc. (“bioLytical”), a global leader in rapid in-vitro medical diagnostics, announced today that it is launching its new testing platform, iStatis, across Europe after receiving its CE Mark for the iStatis COVID-19 Antigen Home Test, allowing its immediate entry into the European market.
Building on its innovative INSTI® testing platform, bioLytical launched iStatis to continue creating reliable access to testing. With new lateral flow technology in its portfolio, bioLytical can reach more people with its COVID-19 antigen home test that provides peace of mind with its industry-leading accuracy of 100%.
“We are excited to announce the addition of iStatis in Europe with our new COVID-19 rapid antigen home test,” said Rob Mackie, Chief Executive Officer of bioLytical. “With our new iStatis platform, we can expand our reach and increase access to testing across Europe. With the unpredictable nature of the pandemic, we are proud to offer Europeans a reliable and trusted test that they can take in the comfort and privacy of their own homes.”
Rapid testing is a vital tool that provides an additional way to identify infection to help reduce virus spread. Along with public health measures such as handwashing, masking, and social distancing, regular rapid testing provides an extra layer of defense against the transmission of the virus. With the pandemic evolving, testing will continue to play an integral role in the fight against COVID-19 by helping keep communities safe.
The iStatis COVID-19 Antigen Home Test will help create certainty in infection identification, providing Europeans with access to a convenient test at home, reducing the burden on busy medical facilities. With its industry-leading accuracy of 100%, portability, and ease of use, iStatis provides reliable results, making informed health decisions easier and quicker.
bioLytical will manufacture the iStatis COVID-19 Antigen Home Tests in its ISO 13485:2016 MDSAP certified facility in Richmond, British Columbia. As a global leader in ultra-rapid infectious disease diagnostics, bioLytical is working to ensure our iStatis COVID-19 Antigen Home Test kits are available across Europe.
bioLytical Laboratories Inc. is a privately-owned Canadian company focused on the research, development, and commercialization of rapid in-vitro medical diagnostics using its proprietary INSTI® technology platform and its lateral flow line iStatis. bioLytical has won several local and industry awards, including B.C. Exporter of the Year in 2019. We have been named Lifesciences B.C.’s Growth Stage Med Tech Company of the Year and are featured on B.C.’s Fastest-Growing Companies for five years in a row, including the Globe and Mail’s Fastest Growing Companies list in 2020. bioLytical moved to a significantly larger, state-of-the-art facility in Richmond, B.C., in 2020 to accommodate the extraordinary growth achieved through our team. Providing accurate results in one minute or less, the INSTI® range includes the INSTI® HIV-1/HIV-2 Antibody Test, INSTI® Multiplex HIV Syphilis Ab Test, INSTI® HIV Self Test, INSTI® Covid-19 Antibody Test, and the INSTI® HCV Antibody Test. bioLytical sells its products in Europe, North America, South America, Africa, and Asia. In 2022, bioLytical launched iStatis, its new lateral flow testing platform to create additional access to testing worldwide.
By delivering accurate results in real-time, INSTI® and iStatis generate meaningful outcomes for medical professionals, patients, and public health organizations worldwide and is a key partner in tackling some of the world’s most severe healthcare challenges. Please visit www.istatis.com, www.insti.com, and www.biolytical.com for more information.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1f4f21c7-51bc-481a-9b13-d4c00f6c2697To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Snam and Golar LNG sign agreement for an FSRU to supply Sardinia with energy18.5.2022 08:15:00 CEST | Press release
San Donato Milanese (Milan), Bermuda – May, 18, 2022 – Snam and Golar LNG Limited (“Golar”) signed a contract through which Golar will deliver the existing LNG Carrier “Golar Arctic” as a floating storage and regasification unit (FSRU) that Snam will install in the port area of Portovesme, in Sardinia, as part of a project to supply the island with energy. The contract, for a total consideration of 269 million euros, includes the vessel and the capex for Golar to convert the Golar Arctic into an FSRU with storage capacity for up to 140,000 cubic meters. Further to the full conversion of the vessel, the FSRU will be sold to the Snam Group. Start of activities for the conversion of the ship into an FSRU and related fulfillments are subject to Snam’s issuance of a Notice-to-Proceed (NTP) and further to that the conversion is expected to take about two years for the Golar Arctic to be delivered. Forward-Looking Statements This press release contains forward-looking statements (as defined i
Sampo completes its share buyback programme18.5.2022 08:15:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 18 May 2022 at 9:15 am Sampo completes its share buyback programme Sampo plc has now completed its share buyback programme. The repurchases of shares began on 31 March 2022 and ended on 17 May 2022. During that period, Sampo repurchased 4,961,994 of its own shares at an average price per share of EUR 45.85. The amount corresponds to 0.9 per cent of all Sampo plc’s shares. The repurchase of own shares has reduced the company's unrestricted equity by approximately EUR 228 million. The purpose of the buyback programme was to return excess capital to shareholders by reducing Sampo plc’s capital, as the repurchased shares will be cancelled. Management intends to propose to the Board that a new share buyback programme is launched after the Annual General Meeting on 18 May 2022, subject to the AGM renewing the Board authorisation on share repurchases. The Board will make a decision on the proposal at the next regular meeting, which takes place on 9 June 2022.
PRESS RELEASE: NACON: CARANTS*! DRAW CLOSER AND SEE THE FIRST IMAGES OF GREEDFALL 218.5.2022 08:00:00 CEST | Press release
CARANTS*! DRAW CLOSER AND SEE THE FIRST IMAGES OF GREEDFALL 2 Lesquin, 18 May 2022 – After the success of GreedFall, with over 2 million copies sold, NACON and the development studio Spiders are pleased to announce a new game: GreedFall 2. Continuing the winning formula of the first game, GreedFall 2 is an RPG that focuses on story and player choice but also includes new gameplay in the form of more tactical combat and revisits the unique universe created by its predecessor. The story starts three years before the events of the first game and the adventures of De Sardet. This time you play as a native of Teer Fradee, uprooted by force from your island and taken to the continent of Gacane, where the colonists are from. In this old world ravaged by war and scarred by the Malichor plague and the political scheming of the different factions, you must regain your freedom and control of your own destiny. Using diplomacy, cunning or combat, as well as help from allies you make, it's up to you
Millicom announces the terms of its rights offering18.5.2022 08:00:00 CEST | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, HONG KONG OR SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. Millicom announces the terms of its rights offering Luxembourg, May 18, 2022 – The board of directors of Millicom International Cellular S.A. (“Millicom”, the “Company” or “we”) has today, making use of the authorization provided for in the Company’s articles of association, resolved on a rights offering (the “Rights Offering”) granting preferential subscription rights to existing holders of sharesand Swedish Depositary Receipts (“SDRs”) to subscribe for up to 70,357,088 shares in aggregate (including in theform of SDRs) and hereby announces the terms of the Rights Offering.
AB Klaipėdos nafta (KN) will hold an Investor Conference Webinar to introduce unaudited financial results for the three months of 202218.5.2022 08:00:00 CEST | Press release
KN invites shareholders, investors, analysts, and other stakeholders to join its investor conference webinar scheduled on the May 27th of 2022 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Mindaugas Kvekšas who will introduce the performance and unaudited financial results of KN for the three months of 2022. After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until May 25th to email@example.com How to join the webinar? To join the webinar, please register via following link:https://nasdaq.zoom.us/webinar/register/WN_aVz8e35rRqO1UC5O3WBp4AYou will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case pl